The clinical RR in patient with TKI therapy who harbored BIM deletion polymorphism was inferior to the patients with BIM wild polymorphism in EGFR-mutated NSCLC population (Ph = 0.349, OR = 0.438, 95%CI = 0.274–0.699). The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.